Although the precise mechanism(s) of neurodegeneration in Parkinson's disease (PD) are unknown, evidence suggests that neuroinflammation is an important contributor. In this study, we will use pre-clinical models of PD to determine whether existing drugs targeting the farnesoid x (a type of hormone) receptor can reduce inflammation and protect dopamine neurons.
This study hypothesizes that drugs targeting the farnesoid x receptor that are currently in clinical trials for other purposes will reduce neuroinflammation in pre-clinical models of PD.
We will use two pre-clinical models of PD that have significant inflammatory components. Existing drugs/compounds that target the farnesoid x receptor will be administered to these models to determine whether they can reduce inflammation and protect dopamine neurons.
Impact on Diagnosis/Treatment of Parkinson's disease:
In one or two sentences, explain how the project holds potential to impact the way Parkinson's is diagnosed and/or treated. Approximately 50 words
Next Steps for Development:
If our experiments are successful, therapies may progress to clinical trials for Parkinson's more rapidly, as they have been in clinical trials for other conditions.